Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.
about
Gq/11-mediated signaling and hypertrophy in mice with cardiac-specific transgenic expression of regulator of G-protein signaling 2Protein kinase cascades in the regulation of cardiac hypertrophyDeregulation of RGS2 in cardiovascular diseasesRationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertensionNovel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood LeukocytesMyocardial hypertrophy and its role in heart failure with preserved ejection fractionRSK3: A regulator of pathological cardiac remodelingRole of soluble epoxide hydrolase in postischemic recovery of heart contractile functionCardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in miceIncreased blood pressure in mice lacking cytochrome P450 2J5Pak1 as a novel therapeutic target for antihypertrophic treatment in the heartEffects of stretch and shortening on gene expression in intact myocardium.Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.Histopathological study of time course changes in inter-renal aortic banding-induced left ventricular hypertrophy of mice.Proteasome inhibitors and cardiac cell growthMechano-signaling in heart failureEpigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in ratsCo-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts.Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure.Regulation of GPCR signaling in hypertension.Expression of a transgene encoding mutant p193/CUL7 preserves cardiac function and limits infarct expansion after myocardial infarctionCalcineurin and cardiac hypertrophy: where have we been? Where are we going?Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease.Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice.Molecular mechanisms of inherited cardiomyopathies.Heart failure -- a challenge to our current concepts of excitation-contraction coupling.Mitochondrial reprogramming induced by CaMKIIδ mediates hypertrophy decompensationBeta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytesPrevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.The left ventricle in aortic stenosis: evidence for the use of ACE inhibitorsCardiac GPCRs: GPCR signaling in healthy and failing hearts.Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.A single strain-based growth law predicts concentric and eccentric cardiac growth during pressure and volume overloadAdiponectin protects against the development of systolic dysfunction following myocardial infarction.Precursors of Hypertensive Heart Phenotype Develop in Healthy Adults: A High-Resolution 3D MRI Study.When 7 transmembrane receptors are not G protein-coupled receptors.Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophyPhosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy.Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation.
P2860
Q21134156-59BE3A98-1D87-41BC-BE5D-A583DBB7179BQ24518494-D2A28575-19EA-48C5-997F-2FAC6198ECC3Q24654920-88879D4E-A3C0-44FE-91B8-70B9D2ED80BAQ24680384-65BD16BE-F662-437F-8EE2-11FE39D3F8E0Q26776138-FEDEEE20-DD5A-40EE-B023-8C696B8FB150Q26800076-DBF7AFF3-F8DA-440B-B986-12DD544C731DQ28086916-344AC42A-02C6-4F53-BC08-CB5F84AC4B29Q28397090-863D389B-53FC-4480-8B0F-F060FE53F18AQ28484674-10FAFFE3-4B18-4EB8-952B-E33ECB9B5E02Q28509705-D55475E4-2A03-494B-BB01-A07E641145E5Q28583542-44D1A3F2-DFAA-46F3-BAA9-A808517EBDEDQ30408585-ABA1FC76-6532-40D7-87B0-5F5B428DBF51Q30477341-5EE76B02-1ABC-448F-AB97-199E2C92116BQ33270074-C9076DA5-897A-4938-9807-ACBD65CF06D8Q33554490-BD045DA7-E036-4E25-9EC5-2923CBD1FD43Q33663368-1FAFFA87-CF6A-4948-AF9B-80FB5E560878Q33860907-713C40C6-7055-454A-AAE7-696C0BB0CAAAQ33888579-068DFBDA-1F51-4405-947A-86C6B987EE48Q34121851-84561266-0D4D-4FD9-8A34-D13DEE8A5F1AQ34273837-A8B8AD4A-887A-4A4B-B207-24D3DCF13A8AQ34488508-65188D8F-BE24-4127-8EFE-B96A577078E3Q34641729-E7C00931-5434-4B28-9EF5-D2D1EB9C4A49Q34706690-2DAB096F-4D75-47B4-86EB-F47A9086A853Q34830604-3387CFA1-07A5-4A20-8442-4FF96AF88DD4Q34882653-FAD344B3-0AC4-4805-B3F3-064A944BA1E0Q35037543-7934D654-2AA2-4209-AFF1-7DD53079BDDDQ35132584-FF601433-1FC3-4514-820F-CE3D6C08CCA1Q35133773-65F3332A-84EE-4C46-8077-79ADE2A52D66Q35214761-EA21D17A-8451-4849-BDD6-DB75B7CE8F41Q35534909-E90AD594-20BC-427D-A0A9-12534B73E5D4Q35771487-6738042B-0F44-4CA9-8D29-18C86F37C777Q35842857-5890BFDE-948F-4692-978A-5263D9A08F8FQ35951476-88A3ADCF-9FE9-46D1-BD74-28A16558844FQ35982552-0546BDF0-2ACC-4AE7-8C69-200AA28789FEQ36004798-3558B86D-EB6D-426C-A182-411634E58597Q36264649-63CCEEE8-DF37-40DD-8E20-577B8FC58290Q36308861-747B7075-EA2B-436E-9FD4-887DAB65F437Q36322902-8689E759-AE74-4245-9551-DD587E73CB6BQ36350066-88527959-D790-44C4-B09A-9DB87EBB977CQ36456843-7BEB1572-ED9C-4B4E-9AD4-712AA1D88265
P2860
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Genetic alterations that inhib ...... despite increased wall stress.
@en
Genetic alterations that inhib ...... despite increased wall stress.
@nl
type
label
Genetic alterations that inhib ...... despite increased wall stress.
@en
Genetic alterations that inhib ...... despite increased wall stress.
@nl
prefLabel
Genetic alterations that inhib ...... despite increased wall stress.
@en
Genetic alterations that inhib ...... despite increased wall stress.
@nl
P2093
P356
P1433
P1476
Genetic alterations that inhib ...... despite increased wall stress
@en
P2093
Hideyuki Takaoka
Howard A Rockman
Sathyamangla V Naga Prasad
Steven A Thomas
Walter J Koch
P356
10.1161/HC0102.101365
P407
P577
2002-01-01T00:00:00Z